Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.48M | -3.97M | -12.30M | -8.30M | -608.00K |
| Total Depreciation and Amortization | 107.00K | -220.00K | 212.00K | 228.00K | 144.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.64M | -1.01M | 2.15M | -183.00K | 267.00K |
| Change in Net Operating Assets | -3.64M | 3.79M | 1.30M | -133.00K | -646.00K |
| Cash from Operations | -11.65M | -1.41M | -8.63M | -8.38M | -843.00K |
| Capital Expenditure | -- | 0.00 | -23.00K | -- | -23.00K |
| Sale of Property, Plant, and Equipment | -- | -6.00K | 2.00K | 3.00K | 89.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.16M | 10.98M | 468.00K | 336.00K | 628.00K |
| Cash from Investing | 15.16M | 10.97M | 447.00K | 339.00K | 694.00K |
| Total Debt Issued | -- | -- | -259.00K | 129.00K | -- |
| Total Debt Repaid | -- | -206.00K | -111.00K | -141.00K | -- |
| Issuance of Common Stock | -- | 0.00 | 2.00K | 17.00K | 8.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -206.00K | -368.00K | 5.00K | 8.00K |
| Foreign Exchange rate Adjustments | 1.15M | -1.31M | 428.00K | -61.00K | -903.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.66M | 8.05M | -8.12M | -8.10M | -1.04M |